Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX
· Real-Time Price · USD
1.69
-0.02 (-1.17%)
At close: May 01, 2025, 3:34 PM
-1.17% (1D)
| Bid | 1.6 |
| Market Cap | 37.17M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -41M |
| EPS (ttm) | -3.51 |
| PE Ratio (ttm) | -0.48 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 1.7 |
| Volume | 27,380 |
| Avg. Volume (20D) | 38,263 |
| Open | 1.72 |
| Previous Close | 1.71 |
| Day's Range | 1.60 - 1.69 |
| 52-Week Range | 1.35 - 4.40 |
| Beta | 2.12 |
About RNTX
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 c...
Industry Medical - Pharmaceuticals
Sector Healthcare
IPO Date Jun 29, 2017
Employees 11
Stock Exchange NASDAQ
Ticker Symbol RNTX
Website http://www.reintx.com